First-line Pembrolizumab Plus Platinum Doublet Chemotherapy With Lenvatinib in Unresectable Malignant Pleural Mesothelioma Multi-Institutional, Single-Arm Phase 2 Trial
Latest Information Update: 30 May 2025
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Lenvatinib (Primary) ; Pemetrexed (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Acronyms PENINSULA
Most Recent Events
- 25 May 2025 Status changed from not yet recruiting to recruiting.
- 21 Mar 2024 New trial record